en
Scientific article
Open access
English

Impact of IL28B, APOH and ITPA polymorphisms on efficacy and safety of TVR- or BOC-based triple therapy in treatment-experienced HCV-1 patients with compensated cirrhosis from the ANRS CO20_CUPIC study

CollaboratorsNegro, Francesco
Published inPLOS ONE, vol. 10, no. 12, e0145105
Publication date2015
Abstract

Human genetic factors influence the outcome of pegylated interferon and ribavirin hepatitis C therapy. We explored the role of IL28B, APOH and ITPA SNPs on the outcomes of triple therapy including telaprevir or boceprevir in patients with compensated cirrhosis chronically infected with HCV-1.

Keywords
  • Anemia/complications
  • Drug Therapy
  • Combination
  • Hemoglobins/metabolism
  • Hepacivirus/physiology
  • Hepatitis C
  • Chronic/complications/drug therapy/genetics/virology
  • Humans
  • Interleukins/genetics
  • Liver Cirrhosis/complications/drug therapy/genetics/virology
  • Oligopeptides/adverse effects/therapeutic use
  • Polymorphism
  • Single Nucleotide/genetics
  • Proline/adverse effects/analogs & derivatives/therapeutic use
  • Pyrophosphatases/genetics
  • Treatment Outcome
  • Beta 2-Glycoprotein I/genetics
Citation (ISO format)
ABOUT, Frédégonde et al. Impact of IL28B, APOH and ITPA polymorphisms on efficacy and safety of TVR- or BOC-based triple therapy in treatment-experienced HCV-1 patients with compensated cirrhosis from the ANRS CO20_CUPIC study. In: PLOS ONE, 2015, vol. 10, n° 12, p. e0145105. doi: 10.1371/journal.pone.0145105
Main files (1)
Article (Published version)
Identifiers
ISSN of the journal1932-6203
201views
105downloads

Technical informations

Creation11/14/2019 4:58:00 PM
First validation11/14/2019 4:58:00 PM
Update time03/15/2023 6:22:04 PM
Status update03/15/2023 6:22:02 PM
Last indexation02/12/2024 11:44:43 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack